In short
This article discusses the clinical trials of LAVA-1207, a new drug designed to treat advanced prostate cancer that has become resistant to other therapies. LAVA-1207 is a bispecific immunotherapy that targets specific proteins on cancer cells and activates the body's immune system to fight the disease. The trials aim to evaluate the safety, effectiveness, and potential benefits of this innovative treatment approach for patients with metastatic castration-resistant prostate cancer.
At a glance
- Drug Name
- LAVA-1207
- Drug Type
- Bispecific immunotherapy (PSMA-targeting γδ-T cell engager)
- Target Condition
- Metastatic castration-resistant prostate cancer (mCRPC)
- Trial Phase
- Phase 1 and 2a
- Trial Design
- Open-label, dose escalation and expansion
- Treatment Arms
- 1. LAVA-1207 alone; 2. LAVA-1207 + low-dose IL-2; 3. LAVA-1207 + pembrolizumab
- Primary Objectives
- Safety, tolerability, and determining recommended Phase 2 dose
- Secondary Objectives
- Antitumor activity, pharmacokinetics, pharmacodynamics, immunogenicity
- Key Eligibility Criteria
- Adult males with mCRPC, prior taxane-based chemotherapy, progression on hormone therapy
- Treatment Duration
- Approximately 24 weeks or until disease progression/unacceptable toxicity
What is LAVA-1207?
LAVA-1207 is a new experimental drug being developed for the treatment of advanced prostate cancer. Its full scientific name is "humanised bispecific immunoglobulin VHH fragments against PSMA and Vgamma9Vdelta2 T-cell receptor". This complex name describes the drug's unique structure and how it works in the body.
The drug is also known by its simpler name, LAVA-1207, which is easier for patients and doctors to use in everyday conversations.
How does LAVA-1207 work?
LAVA-1207 is a type of drug called a bispecific γδ-T cell engager. This means it can bind to two different things at once:
- It attaches to a protein called PSMA (Prostate-Specific Membrane Antigen), which is found on prostate cancer cells.
- It also binds to a specific type of immune cell in your body called Vgamma9Vdelta2 T-cells.
By connecting these two, LAVA-1207 helps your immune system find and attack the cancer cells more effectively. This approach is part of a field called immunotherapy, which uses your body's own defense mechanisms to fight cancer.
What conditions does LAVA-1207 treat?
LAVA-1207 is being developed to treat metastatic castration-resistant prostate cancer (mCRPC). Let's break down what this means:
- Metastatic: The cancer has spread from the prostate to other parts of the body.
- Castration-resistant: The cancer continues to grow even when the levels of male hormones (like testosterone) are reduced to very low levels.
- Prostate cancer: A type of cancer that begins in the prostate gland, which is part of the male reproductive system.
This form of prostate cancer is particularly challenging to treat because it has become resistant to standard hormone therapies.
Current Clinical Trial
LAVA-1207 is currently being tested in a clinical trial called LAVA1207-001/LAVA1207-002. This is a Phase 1 and 2a trial, which means it's in the early stages of testing in humans. The main goals of this trial are to:
- Check if LAVA-1207 is safe to use in patients
- See how well patients tolerate the drug
- Understand how the drug moves through and acts in the body
- Look for early signs that the drug might be working against the cancer
Who can participate in the trial?
The trial is looking for men with advanced prostate cancer who meet specific criteria. Some key points include:
- Must be 18 years or older
- Have metastatic castration-resistant prostate cancer
- Have tried at least one type of chemotherapy (or be unable to receive chemotherapy)
- Have tried at least one newer type of hormone therapy
- Have evidence that their cancer is still growing despite previous treatments
There are also several factors that might prevent someone from participating, such as having certain other medical conditions or infections.
What to expect during the trial
The trial is testing LAVA-1207 in three different ways:
- LAVA-1207 alone: Some patients will receive just LAVA-1207.
- LAVA-1207 with low-dose IL-2: Some patients will receive LAVA-1207 plus a low dose of another drug called interleukin-2, which can help boost the immune system.
- LAVA-1207 with pembrolizumab: Some patients will receive LAVA-1207 plus another immunotherapy drug called pembrolizumab.
Patients will receive LAVA-1207 through an infusion (a slow injection into a vein). The treatment will continue for about 24 weeks, or until the cancer progresses or side effects become too severe.
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to participating in this trial:
Potential benefits:
- Access to a new treatment that might be effective against advanced prostate cancer
- Close monitoring by a team of medical professionals
- Contributing to the advancement of cancer research
Potential risks:
- Unknown side effects, as this is an early-stage trial
- The treatment may not be effective for everyone
- Time commitment for medical visits and procedures
It's important to discuss these potential benefits and risks thoroughly with your doctor before deciding to participate in any clinical trial.